Ensysce Biosciences Enters Material Definitive Agreement
Ticker: ENSCW · Form: 8-K · Filed: Feb 4, 2025 · CIK: 1716947
| Field | Detail |
|---|---|
| Company | Ensysce Biosciences, INC. (ENSCW) |
| Form Type | 8-K |
| Filed Date | Feb 4, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $10 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
TL;DR
Ensysce just signed a big deal, details TBD.
AI Summary
Ensysce Biosciences, Inc. announced on February 4, 2025, that it entered into a material definitive agreement. The filing does not specify the other party or the terms of the agreement, but it is classified under 'Entry into a Material Definitive Agreement' and 'Financial Statements and Exhibits'. The earliest event reported was on January 12, 2025.
Why It Matters
This filing indicates a significant new agreement for Ensysce Biosciences, which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — The lack of specific details about the material definitive agreement introduces uncertainty regarding its impact on the company.
Key Players & Entities
- Ensysce Biosciences, Inc. (company) — Registrant
- February 4, 2025 (date) — Date of Report
- January 12, 2025 (date) — Earliest event reported
- Leisure Acquisition Corp. (company) — Former Company Name
FAQ
What is the nature of the material definitive agreement entered into by Ensysce Biosciences?
The filing does not specify the nature of the material definitive agreement, only that one was entered into on or before February 4, 2025.
Who is the other party to this material definitive agreement?
The filing does not disclose the name of the other party involved in the material definitive agreement.
What are the key terms and financial implications of this agreement?
The filing does not provide any details regarding the terms or financial implications of the agreement.
When was the earliest event related to this agreement reported?
The earliest event reported in relation to this agreement was on January 12, 2025.
What is the primary business of Ensysce Biosciences, Inc.?
Ensysce Biosciences, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
Filing Stats: 775 words · 3 min read · ~3 pages · Grade level 12.6 · Accepted 2025-02-04 17:29:33
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENSC The Nasdaq Stock Mar
- $10 million — t provides for Galephar to expend up to $10 million (the " Cap ") to support research and d
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 118KB
- 0001493152-25-004880.txt ( ) — 351KB
- ensc-20250204.xsd (EX-101.SCH) — 3KB
- ensc-20250204_lab.xml (EX-101.LAB) — 33KB
- ensc-20250204_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 4, 2025 Ensysce Biosciences, Inc. By: /s/ Lynn Kirkpatrick Name: Dr. Lynn Kirkpatrick Title: President and Chief Executive Officer 3